The latest price target for Kura Oncology (NASDAQ:KURA) was reported by UBS on March 6, 2025. The analyst firm set a price target for $14.00 expecting KURA to rise to within 12 months (a possible 93.37% upside). 35 analyst firms have reported ratings in the last year.

The latest analyst rating for Kura Oncology (NASDAQ:KURA) was provided by UBS, and Kura Oncology maintained their buy rating.

There is no last upgrade for Kura Oncology

The last downgrade for Kura Oncology Inc happened on October 14, 2024 when Stifel changed their price target from $26 to $19 for Kura Oncology Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kura Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kura Oncology was filed on March 6, 2025 so you should expect the next rating to be made available sometime around March 6, 2026.

While ratings are subjective and will change, the latest Kura Oncology (KURA) rating was a maintained with a price target of $27.00 to $14.00. The current price Kura Oncology (KURA) is trading at is $7.24, which is out of the analyst’s predicted range.